Inclusion Criteria:  Healthy subjects, aged 18-55 (including boundary); Body mass index (BMI) between 19 to 28 kg/m2 (including boundary), male body weight ≥50 kg and <90 kg , female body weight ≥45kg and <90kg; Participant with no clinically significant findings in vital signs, physical examination, 12-lead ECG ,X-ray and laboratory parameters，etc. Understand the study procedures and methods, voluntary to participate in the study and signed the informed consent.  Exclusion Criteria:  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin/direct bilirubin > 1.2 fold ULN during screening/baseline. Serum creatinine> ULN during screening/baseline. Positive faecal occult blood Abnormal coagulation function. A clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs. Subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before administration. Human immunodeficiency virus antibody, syphilis serological examination, hepatitis b virus surface antigen, hepatitis c virus antibody were positive. 3 months prior to screening involved in any drug or medical device clinical studies. . Female subjects who did not receive contraception at least 30 days before administration and etc.